Statement of Organization, Functions, and Delegations of Authority, 73054-73056 [2020-25194]
Download as PDF
73054
Federal Register / Vol. 85, No. 221 / Monday, November 16, 2020 / Notices
FEDLINE 2021 FEE SCHEDULE—Continued
[Effective January 4, 2021. Bold indicates changes from 2020 prices.]
Fee
51–100 respondents and/or sub-accounts ................................................................................................................
101–500 respondents and/or sub-accounts ..............................................................................................................
>500 respondents and/or sub-accounts ....................................................................................................................
End-of-Day Financial Institution Reconcilement Data (FIRD) File 86 ................................................................................
Statement of Account Spreadsheet File 87 ........................................................................................................................
Intra-day Download Search File (with AMI) 88 ..................................................................................................................
Other:
Software Certification ........................................................................................................................................................
Vendor Pass-Through Fee ................................................................................................................................................
Electronic Access Credit Adjustment ................................................................................................................................
Electronic Access Debit Adjustment .................................................................................................................................
By order of the Board of Governors of the
Federal Reserve System.
Ann Misback,
Secretary of the Board.
[FR Doc. 2020–25176 Filed 11–13–20; 8:45 am]
BILLING CODE P
jbell on DSKJLSW7X2PROD with NOTICES
57 The
incentive discounts apply to the volume
that exceeds 60 percent of a customer’s historic
benchmark volume. Historic benchmark volume is
based on a customer’s average daily activity over
the previous five calendar years. If a customer has
fewer than five full calendar years of previous
activity, its historic benchmark volume is based on
its daily activity for as many full calendar years of
data as are available. If a customer has less than one
year of past activity, then the customer qualifies
automatically for incentive discounts for the year.
The applicable incentive discounts are as follows:
$0.672 for transfers up to 14,000; $0.200 for
transfers 14,001 to 90,000; and $0.132 for transfers
over 90,000.
58 This surcharge applies to originators of
transfers that are processed by the Reserve Banks
after 5:00 p.m. eastern time.
59 This fee is charged to any Fedwire Funds
participant that originates a transfer message via the
FedPayments Manager (FPM) Funds tool and has
the import/export processing option setting active
at any point during the month.
60 Payment Notification and End-of-Day
Origination surcharges apply to each Fedwire funds
transfer message.
61 Provided on billing statement for informational
purposes only.
62 This charge is assessed to settlement
arrangements that use the Fedwire Funds Service to
effect the settlement of interbank obligations (as
opposed to those that use the National Settlement
Service). With respect to such special settlement
arrangements, other charges may be assessed for
each funds transfer into or out of the accounts used
in connection with such arrangements.
63 If your organization is a settlement agent, it
may be able to use the NSS offline service if it is
experiencing an operational event that prevents the
transmission of settlement files via its electronic
connection to the Federal Reserve Banks. The
Federal Reserve Banks have limited capacity to
process offline settlement files. As a result, while
the Federal Reserve Banks use best efforts to
process offline settlement file submissions, there is
no guarantee that an offline settlement file, in
particular one that is submitted late in the operating
day or that contains a large number of entries, will
be accepted for processing. Only those persons
identified as authorized individuals on the NSS 04
Agent Contact Form may submit offline settlement
files. For questions related to the NSS offline
service, please contact NSS Central Support Service
Staff (CSSS) at 800–758–9403, or via email at
csss.staff@ny.frb.org.
VerDate Sep<11>2014
20:13 Nov 13, 2020
Jkt 253001
64 Any settlement arrangement that accrues less
than $60 during a calendar month will be assessed
a variable amount to reach the minimum monthly
fee.
65 These fees are set by the Federal Reserve Banks.
66 This surcharge is set by the Federal Reserve
Banks. It is in addition to any basic transfer or
reversal fee.
67 The Federal Reserve Banks offer an automated
claim adjustment process only for Agency
mortgage-backed securities.
68 This fee is set by and remitted to the
Government National Mortgage Association
(GNMA).
69 The Federal Reserve Banks charge participants
a Joint Custody Origination Surcharge for both
Agency and Treasury securities.
70 FedComplete customers that use the email
service would be charged the FedMail Email a la
carte fee and for all FedMail-FedLine Exchange
Subscriber 5-packs.
71 FedComplete packages are all-electronic
service options that bundle payment services with
an access solution for one monthly fee.
72 Packages with an ‘‘A’’ include the FedLine
Advantage channel, and packages with ‘‘C’’ include
the FedLine Command channel.
73 Per-item surcharges are in addition to the
standard fees listed in the applicable priced
services fee schedules.
74 FedComplete customers will be charged $4 for
each FedForward cash letter over the monthly
package threshold. This activity will appear under
billing code 51998 in Service Area 1521 on a
month-lagged basis.
75 FedMail and FedLine Exchange packages do
not include user credentials, which are required to
access priced services and certain informational
services. Credentials are sold separately in packs of
five via the FedMail-FedLine Exchange Subscriber
5-pack.
76 FedLine Web and Advantage packages do not
include user credentials, which are required to
access priced services and certain informational
services. Credentials are sold separately in packs of
five via the FedLine Subscriber 5-pack.
77 Early termination fees and/or expedited order
fees may apply to all FedLine Direct packages and
FedLine Direct a la carte options.
78 These add-on services can be purchased only
with a FedLine Solutions packages.
79 Additional VPNs are available for FedLine
Advantage, FedLine Command, and FedLine Direct
packages only.
80 These upgrades are only available for the new
FedLine Direct packages and the Add’l 2M WAN
connection. Fee is in addition to the FedLine Direct
package fees or additional WAN fees.
81 The FedLine Custom Implementation Fee is
$2,500 or $5,000 based on the complexity of the
setup.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
$500.00.
$750.00.
$1,000.00.
$150.00.
$150.00.
$150.00.
$0.00 to $8,000.00.
various.
various.
various.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 85 FR 30106–30708,
dated May 20, 2020) is amended to
reflect the reorganization of the Division
of Sexually Transmitted Disease
Prevention within the National Center
for HIV/AIDS, Viral Hepatitis, STD, and
TB Prevention, Centers for Disease
Control and Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows:
Delete in its entirety the titles and
mission and function statements for the
Division of Sexually Transmitted
Disease Prevention (CVJD) and insert
the following:
82 Available only to customers with a priced
FedLine package.
83 Limited to installed base only.
84 Five download codes are included at no cost
in all Plus and Premier packages.
85 Cash Management Service options are limited
to plus and premier packages.
86 The End of Day Reconcilement File option is
available for FedLine Web Plus, FedLine Advantage
Plus, and Premier packages. It is available for no
extra fee in FedLine Command Plus and Direct
packages.
87 The Statement of Account Spreadsheet File
option is available for FedLine Web Plus, FedLine
Advantage Plus, and Premier packages. It is
available for no extra fee in FedLine Command Plus
and Direct packages.
88 The Intra-day Download Search File option is
available for the FedLine Web Plus package. It is
available for no extra fee in FedLine Advantage and
higher packages.
E:\FR\FM\16NON1.SGM
16NON1
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 85, No. 221 / Monday, November 16, 2020 / Notices
Division of Sexually Transmitted
Disease Prevention (CVJD). (1) In
cooperation with other CDC
components, administers operational
programs for the prevention of sexually
transmitted diseases (STD); (2) provides
consultation, training, statistical,
educational, epidemiological, and other
technical services to assist state and
local health departments in the
planning, development,
implementation, evaluation, and overall
improvement of STD prevention
programs; (3) supports a nationwide
framework for effective surveillance of
STD other than HIV; (4) conducts
behavioral, clinical, epidemiological,
preventive health services, and
operational research into factors
affecting the prevention and control of
STD; (5) provides leadership and
coordinates, in collaboration with other
CDC components, research and program
activities that focus on STD and HIV
prevention; (6) promotes linkages
between health department STD
programs and other governmental and
non-governmental partners who are
vital to effective STD prevention efforts;
(7) provides technical supervision for
division, state and local assignees; and
(8) collaborates with other components
of the division, NCHHSTP and CDC to
develop and implement strategies and
activities to meet goals for key division
priorities.
Office of the Director (CVJD1). (1)
Plans, directs and evaluates the
activities of the division; (2) provides
national leadership and guidance in
STD science, surveillance, prevention
and control policy formulation; program
planning, development, management,
and evaluation; development of
training, educational, and health
communications; (3) provides
operational, administrative, fiscal,
technical, and logistical support for
division programs and units; (4) assures
multidisciplinary collaboration in STD
prevention and control activities; (5) in
cooperation with other CDC
components, provides leadership for
developing research relevant to STD
prevention and control; (6) provides
leadership, guidance, and coordinates
development of guidelines and
standards to assure ongoing high-quality
performance of STD prevention and
control programs; (7) coordinates global
STD activity of the division; (8)
collaborates, as appropriate, with other
divisions and offices in NCHHSTP, and
with other divisions throughout CDC;
(9) collaborates as appropriate with
external organizations outside of CDC to
achieve the mission of the division; and
VerDate Sep<11>2014
20:13 Nov 13, 2020
Jkt 253001
(10) manages the Tuskegee Participants
Health Benefits Program.
STD Laboratory Reference and
Research Branch (CVJDE). (1) Performs
research on the pathogenesis, genetics,
and immunology of syphilis, gonococcal
and chlamydial infections, and other
sexually transmitted infections (STI),
including rare (e.g., chancroid) or
emerging (e.g., Mycoplasma genitalium)
STI; (2) conducts research and reference
services to develop, evaluate, and
improve laboratory STI diagnostics and
methods; (3) participates in the design,
implementation, and analysis of
national and international STD
epidemiology studies, surveillance
activities, and biomedical interventions;
(4) conducts laboratory-based
surveillance for and research on the
genetics of antimicrobial resistance in
Neisseria gonorrhoeae and for other
STIs; (5) serves as the WHO
International Collaborating Center for
Reference and Research in STI and as
reference laboratory for WHO STD
diagnostics and surveillance initiatives;
and (6) develops STD laboratory
guidelines.
Program Development and Evaluation
Branch (CVJDG). (1) Provides and
facilitates technical assistance and
capacity building to state and local
health departments, non-governmental,
and other partners in the planning,
implementation, and evaluation of STD
prevention and control strategies; (2)
monitors and evaluates STD prevention
strategies to assure programmatic
objectives are being met and to track
individual and collective progress over
time; (3) conducts analysis of STD
prevention and control strategies and
collaborates with partners to resolve
challenges and increase awareness of
best practices; (4) develops and manages
programs, solicitations, and evaluation
projects to advance innovations and
quality improvements in STD
prevention and control strategies and
activities; and (5) supports the
identification, translation,
dissemination, and adoption of
evidence-based interventions and
practices by state and local health
departments, non-governmental, and
other prevention partners.
Surveillance and Data Science Branch
(CVJDH). (1) Assesses and disseminates
data on STD burden, risks, and trends
in STD morbidity and mortality; (2)
leads, evaluates, and provides
recommendations for improving STD
surveillance systems; (3) provides
leadership in the management and
coordination of information systems
that can electronically receive, store,
and transmit STD surveillance and case
management data; (4) provides
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
73055
surveillance, data management and
public health informatics technical
assistance and support to the division,
local and state health departments, and
other national and international
partners; and (5) translates informatics
best practices for STD electronic case
reporting, clinical decision support, and
other division efforts.
Disease Intervention and Response
Branch (CVJDJ). (1) Investigates STDs in
the community (e.g., field testing, public
health detailing, outbreak response, and
contact tracing); (2) provides technical
assistance and capacity in disease
investigation to support communities
and public health partners; (3) conducts
activities to assure a competent disease
investigation workforce (e.g., DIS
certification, mentoring and training);
and (4) provides linkage to services for
STD prevention and control and other
co-occurring activities (e.g., intimate
partner violence, behavioral health, HIV
care, PrEP, and reproductive health
services).
Behavioral Science and Epidemiology
Branch (CVJDK). (1) Synthesizes
evidence and critically appraises
existing prevention science research, as
related to STD priorities; (2) identifies
and describes the context for effective
STD prevention science; (3) provides
national and international leadership in
the design and dissemination of studies
to implement STD prevention
interventions at individual, group,
community, and structural levels; and
(4) translates or adapts research
strategies and evaluation results from
formative assessments and prevention
interventions for programmatic action
and to inform national STD prevention
policy and program direction.
Clinical, Economics, and Health
Services Research Branch (CVJDL). (1)
Develops and evaluates methodologies
for conducting clinical, economic,
modelling, and health services research
related to STD prevention and control;
(2) develops preventive clinical, health
services, transmission dynamics, and
cost-effectiveness models for STDrelated issues; (3) estimates the
economic and health impact burden of
STDs and cost-effectiveness of STD
prevention; (4) develops, disseminates,
and evaluates STD prevention and
clinical guidelines; (5) provides
technical assistance, training, and
capacity building pertaining to clinical
and health services-related aspects of
STD prevention; and (6) provides
statistical research and technical
E:\FR\FM\16NON1.SGM
16NON1
73056
Federal Register / Vol. 85, No. 221 / Monday, November 16, 2020 / Notices
assistance to others in the division and
to local and state STD control programs.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2020–25194 Filed 11–13–20; 8:45 am]
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–D–3592]
Certificates of Confidentiality;
Guidance for Sponsors, SponsorInvestigators, Researchers, Industry,
and Food and Drug Administration
Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a final
guidance entitled ‘‘Certificates of
Confidentiality; Guidance for Sponsors,
Sponsor-Investigators, Researchers,
Industry, and Food and Drug
Administration Staff.’’ This guidance is
intended to explain FDA
implementation of the revised statutory
provisions applicable to the request for,
and issuance of, a Certificate of
Confidentiality (CoC). The 21st Century
Cures Act (Cures Act) amended the
statutory provisions relating to the
issuance of CoCs. A CoC is intended to
help protect the privacy of human
subject research participants from
whom sensitive and identifiable
information is being collected or used in
furtherance of the research. Historically,
a CoC generally protected a researcher
from being compelled in a legal
proceeding to disclose identifiable
sensitive information about the research
participant, created or compiled for the
research. As amended, a CoC prohibits
a researcher from disclosing such
information unless a specified exception
applies. This guidance finalizes the
draft guidance of the same title issued
on November 25, 2019.
DATES: The announcement of the
guidance is published in the Federal
Register on November 16, 2020.
ADDRESSES: You may submit either
electronic or written comments on any
guidance at any time as follows:
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
VerDate Sep<11>2014
20:13 Nov 13, 2020
Jkt 253001
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2019–D–3592 for ‘‘Certificates of
Confidentiality; Guidance for Sponsors,
Sponsor-Investigators, Researchers,
Industry, and Food and Drug
Administration Staff.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of this guidance to the Office of
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 32,
Rm. 4248, Silver Spring, MD 20993–
0002. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the final guidance document.
FOR FURTHER INFORMATION CONTACT:
Jarilyn Dupont, Office of Policy, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 4248,
Silver Spring, MD 20993–0002, 301–
796–4716.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a final guidance to explain FDA’s
implementation of the revised
provisions applicable to the request for,
and issuance of, a discretionary CoC.
The Cures Act (Pub. L. 114–255, section
2012) amended the Public Health
Service Act, section 301(d) (42 U.S.C.
241(d)), relating to the issuance of CoCs.
A CoC is intended to help protect the
privacy of human subject research
participants from whom identifiable,
E:\FR\FM\16NON1.SGM
16NON1
Agencies
[Federal Register Volume 85, Number 221 (Monday, November 16, 2020)]
[Notices]
[Pages 73054-73056]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-25194]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Statement of Organization, Functions, and Delegations of
Authority
Part C (Centers for Disease Control and Prevention) of the
Statement of Organization, Functions, and Delegations of Authority of
the Department of Health and Human Services (45 FR 67772-76, dated
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as
amended most recently at 85 FR 30106-30708, dated May 20, 2020) is
amended to reflect the reorganization of the Division of Sexually
Transmitted Disease Prevention within the National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control
and Prevention.
Section C-B, Organization and Functions, is hereby amended as
follows:
Delete in its entirety the titles and mission and function
statements for the Division of Sexually Transmitted Disease Prevention
(CVJD) and insert the following:
[[Page 73055]]
Division of Sexually Transmitted Disease Prevention (CVJD). (1) In
cooperation with other CDC components, administers operational programs
for the prevention of sexually transmitted diseases (STD); (2) provides
consultation, training, statistical, educational, epidemiological, and
other technical services to assist state and local health departments
in the planning, development, implementation, evaluation, and overall
improvement of STD prevention programs; (3) supports a nationwide
framework for effective surveillance of STD other than HIV; (4)
conducts behavioral, clinical, epidemiological, preventive health
services, and operational research into factors affecting the
prevention and control of STD; (5) provides leadership and coordinates,
in collaboration with other CDC components, research and program
activities that focus on STD and HIV prevention; (6) promotes linkages
between health department STD programs and other governmental and non-
governmental partners who are vital to effective STD prevention
efforts; (7) provides technical supervision for division, state and
local assignees; and (8) collaborates with other components of the
division, NCHHSTP and CDC to develop and implement strategies and
activities to meet goals for key division priorities.
Office of the Director (CVJD1). (1) Plans, directs and evaluates
the activities of the division; (2) provides national leadership and
guidance in STD science, surveillance, prevention and control policy
formulation; program planning, development, management, and evaluation;
development of training, educational, and health communications; (3)
provides operational, administrative, fiscal, technical, and logistical
support for division programs and units; (4) assures multidisciplinary
collaboration in STD prevention and control activities; (5) in
cooperation with other CDC components, provides leadership for
developing research relevant to STD prevention and control; (6)
provides leadership, guidance, and coordinates development of
guidelines and standards to assure ongoing high-quality performance of
STD prevention and control programs; (7) coordinates global STD
activity of the division; (8) collaborates, as appropriate, with other
divisions and offices in NCHHSTP, and with other divisions throughout
CDC; (9) collaborates as appropriate with external organizations
outside of CDC to achieve the mission of the division; and (10) manages
the Tuskegee Participants Health Benefits Program.
STD Laboratory Reference and Research Branch (CVJDE). (1) Performs
research on the pathogenesis, genetics, and immunology of syphilis,
gonococcal and chlamydial infections, and other sexually transmitted
infections (STI), including rare (e.g., chancroid) or emerging (e.g.,
Mycoplasma genitalium) STI; (2) conducts research and reference
services to develop, evaluate, and improve laboratory STI diagnostics
and methods; (3) participates in the design, implementation, and
analysis of national and international STD epidemiology studies,
surveillance activities, and biomedical interventions; (4) conducts
laboratory-based surveillance for and research on the genetics of
antimicrobial resistance in Neisseria gonorrhoeae and for other STIs;
(5) serves as the WHO International Collaborating Center for Reference
and Research in STI and as reference laboratory for WHO STD diagnostics
and surveillance initiatives; and (6) develops STD laboratory
guidelines.
Program Development and Evaluation Branch (CVJDG). (1) Provides and
facilitates technical assistance and capacity building to state and
local health departments, non-governmental, and other partners in the
planning, implementation, and evaluation of STD prevention and control
strategies; (2) monitors and evaluates STD prevention strategies to
assure programmatic objectives are being met and to track individual
and collective progress over time; (3) conducts analysis of STD
prevention and control strategies and collaborates with partners to
resolve challenges and increase awareness of best practices; (4)
develops and manages programs, solicitations, and evaluation projects
to advance innovations and quality improvements in STD prevention and
control strategies and activities; and (5) supports the identification,
translation, dissemination, and adoption of evidence-based
interventions and practices by state and local health departments, non-
governmental, and other prevention partners.
Surveillance and Data Science Branch (CVJDH). (1) Assesses and
disseminates data on STD burden, risks, and trends in STD morbidity and
mortality; (2) leads, evaluates, and provides recommendations for
improving STD surveillance systems; (3) provides leadership in the
management and coordination of information systems that can
electronically receive, store, and transmit STD surveillance and case
management data; (4) provides surveillance, data management and public
health informatics technical assistance and support to the division,
local and state health departments, and other national and
international partners; and (5) translates informatics best practices
for STD electronic case reporting, clinical decision support, and other
division efforts.
Disease Intervention and Response Branch (CVJDJ). (1) Investigates
STDs in the community (e.g., field testing, public health detailing,
outbreak response, and contact tracing); (2) provides technical
assistance and capacity in disease investigation to support communities
and public health partners; (3) conducts activities to assure a
competent disease investigation workforce (e.g., DIS certification,
mentoring and training); and (4) provides linkage to services for STD
prevention and control and other co-occurring activities (e.g.,
intimate partner violence, behavioral health, HIV care, PrEP, and
reproductive health services).
Behavioral Science and Epidemiology Branch (CVJDK). (1) Synthesizes
evidence and critically appraises existing prevention science research,
as related to STD priorities; (2) identifies and describes the context
for effective STD prevention science; (3) provides national and
international leadership in the design and dissemination of studies to
implement STD prevention interventions at individual, group, community,
and structural levels; and (4) translates or adapts research strategies
and evaluation results from formative assessments and prevention
interventions for programmatic action and to inform national STD
prevention policy and program direction.
Clinical, Economics, and Health Services Research Branch (CVJDL).
(1) Develops and evaluates methodologies for conducting clinical,
economic, modelling, and health services research related to STD
prevention and control; (2) develops preventive clinical, health
services, transmission dynamics, and cost-effectiveness models for STD-
related issues; (3) estimates the economic and health impact burden of
STDs and cost-effectiveness of STD prevention; (4) develops,
disseminates, and evaluates STD prevention and clinical guidelines; (5)
provides technical assistance, training, and capacity building
pertaining to clinical and health services-related aspects of STD
prevention; and (6) provides statistical research and technical
[[Page 73056]]
assistance to others in the division and to local and state STD control
programs.
Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-25194 Filed 11-13-20; 8:45 am]
BILLING CODE 4160-18-P